Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1030 - APOLLON study: a phase I/II study for the safety and efficacy of panitumumab in combination with TAS-102 for patients with RAS wild-type metastatic colorectal cancer refractory to standard chemotherapy


08 Oct 2016


Poster Display


Kensei Yamaguchi


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


K. Yamaguchi1, Y. Komatsu2, E. Oki3, T. Yoshino4, K. Yamazaki5, K. Shibuya6, K. Oba7, T. Kato8

Author affiliations

  • 1 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 2 Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3 Surgery And Science, Graduate School Of Medical Sciences, Kyushu University, Fukuoka/JP
  • 4 Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 5 Gastrointestinal Oncology And Endoscop, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 6 Medical Affairs, Takeda Pharmaceutical Company Ltd., 108-8668 - Tokyo/JP
  • 7 Dept. Of Biostatistics, School Of Public Health, Graduate School Of Medicine, University of Tokyo, 113-0033 - Tokyo/JP
  • 8 Gastrointestinal Surgery, Kansai Rosai Hospital, 660-8511 - Amagasaki/JP


Abstract 1030


Anti-EGFR antibodies (Panitumumab (Pmab)/Cetuximab (Cmab)) have established efficacy and manageable safety profiles either in monotherapy or in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC) patients (pts). In recent global phase III RECOURCE study, TAS-102 significantly improved OS and PFS over placebo for mCRC pts refractory to standard therapies. In preclnical models, the combination of Pmab with TAS-102 demonstrated enhanced activities compared with either drug alone. This phase I/II study is designed to investigate the safety and efficacy of Pmab combination with TAS-102 for pts with RAS (KRAS/NRAS) wild-type mCRC refractory to standard chemotherapy.

Trial design

Eligible pts are aged 20-74 y, ECOG performance status 0-1 with histologically/cytologically confirmed RAS wild-type mCRC, and refractory or intolerant to fluoropyrimidines, irinotecan, oxaliplatin, and anti-angiogenesis therapy and had neither prior anti-EGFR antibody nor regorafenib treatment. Phase I part is designed to determine recommended phase II dose (RP2D) in the dose de-escalation design of Pmab (6 mg/kg) every 2 weeks combination with TAS-102 (35 mg/m2 BID on days 1–5 and 8–12, every 4 weeks). The primary objectives are to evaluate the incidence proportion of DLTs (phase I) and to evaluate the investigator assessed PFS rate at 6 months (phase II). In order to evaluate the effect of TAS-102 in addition to Pmab monotherapy, an exact binomial test with a nominal one-sided 5% significance level was predicted to have at least 80% power to detect the difference between the null hypothesis proportion of 29% PFS rate and the alternative proportion of 48% PFS rate with the sample size of 47 patients. To assure an adequate number of evaluable patients, target number of subjects are defined 52 (addition to Phase I patients administered with RP2D). As of May 2016, 6 pts have been enrolled. Results are expected in 2017.

Clinical trial identification

ClinicalTrials.gov NCT02613221

Legal entity responsible for the study

MHLW, Japan.


Takeda pharmaceutical Co., ltd.


K. Yamaguchi: Honoraria (speaker's bureau): Takeda, Taiho, Merch, Chugai, Eli-Lily: Research funding for clinical trials from Takeda. Y. Komatsu: Honoraria (speaker's bureau) and Research funding from Novartis, Pfizer, Bayer, Yakult, Daiichi-Sankyo, Kyowa-Kirin, Chugai, Merck-Serono, BMS, Taiho, Takeda, Eli-Lilly. E. Oki: has received Honoraria (lecture fee) from Takeda, Taiho. T. Yoshino: Research funding for clinical trials from GlaxoSmithKline, Boehringer Ingelheim. K. Yamazaki: Honoraria (lecture and/or manuscript fee) from Bayer, Yakult, Daiichi-Sankyo, Chugai, Merck-Serono, BMS, Taiho, Takeda. Research funding from BMS. K. Shibuya: Employee of Takeda. K. Oba: Honoraria (lecture and/or manuscript fee) from Takeda, BMS, Ono, Chugai. T. Kato: Honoraria (lecture fee) from Bayer, Yakult, Chugai, Merck-Serono, Takeda.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings